2026 Q2 - tulosraportti
44 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 119 | - | - | ||
| 1 414 | - | - | ||
| 99 | - | - | ||
| 1 119 | - | - | ||
| 1 408 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·14 min sittenI note the enormous sums now being raised around biotech and AI-driven drug development, while Norwegian biotech still seems quite overlooked. My main sources are mostly LinkedIn pages like Medwatch, Regeneron, Moderna, etc. as well as The New England Journal of Medicine (https://www.nejm.org/). American Isomorphic Labs recently raised $2.1B to scale its AI-driven drug discovery platform, while Dutch Forbion has just raised €2.3B in new life science funds. Forbion itself states that they now sit with large amounts of dry powder in a market characterized by capital scarcity. When one additionally sees how active Big Pharma has been with acquisitions, partnerships, and strategic investments over the past year, I do not think this makes Norwegian biotech any less interesting. Quite the contrary. Nykode is in my opinion very interestingly positioned in this picture: immuno-oncology, individualized treatment, NeoSELECT, proprietary vaccine platform, and potentially 15 to 20 years of proprietary biological and clinical data. The big question for me is how much of this historical dataset is actually structured, digitized, and legally available for AI training. If Nykode sits on a large, proprietary, and AI-ready dataset already linked to actual immune responses and clinical outcomes, this in itself could be a significant strategic asset. Not only for NeoSELECT and Nykode's own programs, but potentially also for external partners wanting proprietary biological data and human validation. I therefore believe that Nykode's value going forward may not solely be judged by the next clinical readout in H2 2027. The data, the platform, and the learning loop may prove to be at least as interesting.
·1 päivä sittenthis is bull for VB10.NEO partner process: https://www.businesswire.com/news/home/20261007586639/en/Tempus-Announces-Multi-Year-Collaboration-with-Moderna-and-Merck?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmark
But will there hardly be an evt partner before they see the next readings around the second half of 2027 ?
·2 päivää sitten · MuokattuFirst time posting a positive comment., or bulling as it is often said., here it blows soon🫡
could well be that you are right Donnie, looks like there is support for 3.54 and that could mean that short selling is done, Everyone wants the stock to go upwards even those who try to press the price down to buy cheap.- ·5.10.Interesting article about what is happening in biotech right now: https://www.finansavisen.no/helse/2026/10/04/8385012/gullrush-i-biotek Nykode is, in my opinion, strategically positioned right in the sweet spot. If you, like me, have great faith in the combination of artificial intelligence and biotech, I think Nykode is the most interesting case on the Oslo Stock Exchange. Part of what I find particularly exciting is the data the company has built up over nearly 20 years. This applies not only to the trials that have succeeded. Also data from experiments that did not yield the desired result can be valuable when teaching models what does not work. All historical data has been preserved, and during the Q&A after the Q2 presentation, Agnete Fredriksen was asked whether new data is fed back into NeoSELECT and used to make the model better over time. The answer was yes. It is precisely this that Finansavisen describes as "lab-in-the-loop": the model suggests, the laboratory tests, the results are fed back, and the next round can be better. This does not mean that AI alone makes Nykode a winner. Clinical results are still what counts. But if Nykode manages to combine 20 years of biological data, NeoSELECT, its own laboratory tests and clinical data in an increasingly better learning loop, then in my opinion it could become a significant competitive advantage. This is a part of the Nykode case that I believe the market is currently paying relatively little attention to. The AI models can eventually be accessed by everyone. 20 years of proprietary biological and clinical data cannot simply be downloaded.
·2.10.It goes without saying that they bought over 500,000 :)
Don't know if I would say it "goes without saying" to put that much into a pennystock. With that said, it is a better one of its kind.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
44 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·14 min sittenI note the enormous sums now being raised around biotech and AI-driven drug development, while Norwegian biotech still seems quite overlooked. My main sources are mostly LinkedIn pages like Medwatch, Regeneron, Moderna, etc. as well as The New England Journal of Medicine (https://www.nejm.org/). American Isomorphic Labs recently raised $2.1B to scale its AI-driven drug discovery platform, while Dutch Forbion has just raised €2.3B in new life science funds. Forbion itself states that they now sit with large amounts of dry powder in a market characterized by capital scarcity. When one additionally sees how active Big Pharma has been with acquisitions, partnerships, and strategic investments over the past year, I do not think this makes Norwegian biotech any less interesting. Quite the contrary. Nykode is in my opinion very interestingly positioned in this picture: immuno-oncology, individualized treatment, NeoSELECT, proprietary vaccine platform, and potentially 15 to 20 years of proprietary biological and clinical data. The big question for me is how much of this historical dataset is actually structured, digitized, and legally available for AI training. If Nykode sits on a large, proprietary, and AI-ready dataset already linked to actual immune responses and clinical outcomes, this in itself could be a significant strategic asset. Not only for NeoSELECT and Nykode's own programs, but potentially also for external partners wanting proprietary biological data and human validation. I therefore believe that Nykode's value going forward may not solely be judged by the next clinical readout in H2 2027. The data, the platform, and the learning loop may prove to be at least as interesting.
- ·1 päivä sittenthis is bull for VB10.NEO partner process: https://www.businesswire.com/news/home/20261007586639/en/Tempus-Announces-Multi-Year-Collaboration-with-Moderna-and-Merck?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmarkBut will there hardly be an evt partner before they see the next readings around the second half of 2027 ?
- ·2 päivää sitten · MuokattuFirst time posting a positive comment., or bulling as it is often said., here it blows soon🫡could well be that you are right Donnie, looks like there is support for 3.54 and that could mean that short selling is done, Everyone wants the stock to go upwards even those who try to press the price down to buy cheap.
- ·5.10.Interesting article about what is happening in biotech right now: https://www.finansavisen.no/helse/2026/10/04/8385012/gullrush-i-biotek Nykode is, in my opinion, strategically positioned right in the sweet spot. If you, like me, have great faith in the combination of artificial intelligence and biotech, I think Nykode is the most interesting case on the Oslo Stock Exchange. Part of what I find particularly exciting is the data the company has built up over nearly 20 years. This applies not only to the trials that have succeeded. Also data from experiments that did not yield the desired result can be valuable when teaching models what does not work. All historical data has been preserved, and during the Q&A after the Q2 presentation, Agnete Fredriksen was asked whether new data is fed back into NeoSELECT and used to make the model better over time. The answer was yes. It is precisely this that Finansavisen describes as "lab-in-the-loop": the model suggests, the laboratory tests, the results are fed back, and the next round can be better. This does not mean that AI alone makes Nykode a winner. Clinical results are still what counts. But if Nykode manages to combine 20 years of biological data, NeoSELECT, its own laboratory tests and clinical data in an increasingly better learning loop, then in my opinion it could become a significant competitive advantage. This is a part of the Nykode case that I believe the market is currently paying relatively little attention to. The AI models can eventually be accessed by everyone. 20 years of proprietary biological and clinical data cannot simply be downloaded.
- ·2.10.It goes without saying that they bought over 500,000 :)Don't know if I would say it "goes without saying" to put that much into a pennystock. With that said, it is a better one of its kind.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 119 | - | - | ||
| 1 414 | - | - | ||
| 99 | - | - | ||
| 1 119 | - | - | ||
| 1 408 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
44 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·14 min sittenI note the enormous sums now being raised around biotech and AI-driven drug development, while Norwegian biotech still seems quite overlooked. My main sources are mostly LinkedIn pages like Medwatch, Regeneron, Moderna, etc. as well as The New England Journal of Medicine (https://www.nejm.org/). American Isomorphic Labs recently raised $2.1B to scale its AI-driven drug discovery platform, while Dutch Forbion has just raised €2.3B in new life science funds. Forbion itself states that they now sit with large amounts of dry powder in a market characterized by capital scarcity. When one additionally sees how active Big Pharma has been with acquisitions, partnerships, and strategic investments over the past year, I do not think this makes Norwegian biotech any less interesting. Quite the contrary. Nykode is in my opinion very interestingly positioned in this picture: immuno-oncology, individualized treatment, NeoSELECT, proprietary vaccine platform, and potentially 15 to 20 years of proprietary biological and clinical data. The big question for me is how much of this historical dataset is actually structured, digitized, and legally available for AI training. If Nykode sits on a large, proprietary, and AI-ready dataset already linked to actual immune responses and clinical outcomes, this in itself could be a significant strategic asset. Not only for NeoSELECT and Nykode's own programs, but potentially also for external partners wanting proprietary biological data and human validation. I therefore believe that Nykode's value going forward may not solely be judged by the next clinical readout in H2 2027. The data, the platform, and the learning loop may prove to be at least as interesting.
- ·1 päivä sittenthis is bull for VB10.NEO partner process: https://www.businesswire.com/news/home/20261007586639/en/Tempus-Announces-Multi-Year-Collaboration-with-Moderna-and-Merck?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmarkBut will there hardly be an evt partner before they see the next readings around the second half of 2027 ?
- ·2 päivää sitten · MuokattuFirst time posting a positive comment., or bulling as it is often said., here it blows soon🫡could well be that you are right Donnie, looks like there is support for 3.54 and that could mean that short selling is done, Everyone wants the stock to go upwards even those who try to press the price down to buy cheap.
- ·5.10.Interesting article about what is happening in biotech right now: https://www.finansavisen.no/helse/2026/10/04/8385012/gullrush-i-biotek Nykode is, in my opinion, strategically positioned right in the sweet spot. If you, like me, have great faith in the combination of artificial intelligence and biotech, I think Nykode is the most interesting case on the Oslo Stock Exchange. Part of what I find particularly exciting is the data the company has built up over nearly 20 years. This applies not only to the trials that have succeeded. Also data from experiments that did not yield the desired result can be valuable when teaching models what does not work. All historical data has been preserved, and during the Q&A after the Q2 presentation, Agnete Fredriksen was asked whether new data is fed back into NeoSELECT and used to make the model better over time. The answer was yes. It is precisely this that Finansavisen describes as "lab-in-the-loop": the model suggests, the laboratory tests, the results are fed back, and the next round can be better. This does not mean that AI alone makes Nykode a winner. Clinical results are still what counts. But if Nykode manages to combine 20 years of biological data, NeoSELECT, its own laboratory tests and clinical data in an increasingly better learning loop, then in my opinion it could become a significant competitive advantage. This is a part of the Nykode case that I believe the market is currently paying relatively little attention to. The AI models can eventually be accessed by everyone. 20 years of proprietary biological and clinical data cannot simply be downloaded.
- ·2.10.It goes without saying that they bought over 500,000 :)Don't know if I would say it "goes without saying" to put that much into a pennystock. With that said, it is a better one of its kind.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 119 | - | - | ||
| 1 414 | - | - | ||
| 99 | - | - | ||
| 1 119 | - | - | ||
| 1 408 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt